Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing

In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens

(2018) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid

(2016) M. Zeitlinger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism

(2016) Zohar Eyal et al.   Scientific Reports

Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections

(2014) C. M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase II Clinical Study of BC-3781, a Pleuromutilin Antibiotic, in Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections

(2013) W. T. Prince et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010

(2013) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections

(2012) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

(2012) H. S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome

(2003) Susan M. Poulsen et al.   MOLECULAR MICROBIOLOGY